Annovis Achieves Key Milestones in Alzheimer's and Parkinson's Programs, Reports Encouraging Biomarker Data and Initiates Phase 3 Trial in Early Alzheimer's Disease.

Annovis Bio, a biotechnology company, reported its fiscal year 2025 financial results and provided corporate updates. The company initiated a pivotal Phase 3 clinical trial in early Alzheimer's disease, achieved a significant milestone, and enrolled 65% of the target population across 83 clinical sites in the US. Annovis also reported encouraging data from previous Alzheimer's and Parkinson's programs, demonstrating a potential disease-modifying signal for buntanetap, and initiated an open-label extension study in Parkinson's disease.